ELT Sight announced the company has acquired the IP and assets of MLase AG’s excimer ophthalmic laser system for glaucoma surgery.
Terms for the acquisition were not disclosed.
MLase manufactures and markets laser systems, including the ExTra ELT Laser and disposable applicator used to perform implant-free, microinvasive glaucoma surgery. The system received European CE Mark certification in 2014 and is currently available in Europe. ELT Sight plans to expand marketing activities in Europe and initiate clinical studies in the United States in early 2020.
Excimer Laser Trabeculostomy (ELT) is an implant-free microinvasive glaucoma surgery that was first used clinically in Europe in 1997. This outpatient procedure has shown superior results and a favorable safety profile in European studies with sustained, multi-year reduced IOP and decreased medication use.
“There is a growing need for new solutions to address glaucoma, a global health challenge expected to affect 80 million people worldwide in 2020. Clinical studies in Europe have demonstrated that the ExTra ELT Laser system offers patients with glaucoma an implant-free choice to lower eye pressure,” Elliott Friedman, Chief Executive Officer of ELT Sight, said in a company news release. “Our hope is to simultaneously ramp up marketing activities in Europe while conducting clinical trials in the United States early next year.”
The ExTra ELT Laser and disposable applicator will continue to be manufactured by MLase in Germany. ELT treats the pathology leading to open-angle glaucoma exactly where it occurs by increasing the permeability of the trabecular meshwork, with studies showing lower risks than other treatment methods. The outpatient procedure is completed in less than 10 minutes.
“MLase has an excellent reputation for developing and manufacturing innovative laser systems, and we look forward to collaborating with them as we focus on making this system available to the millions of patients affected by glaucoma worldwide,” Mr. Friedman said in the news release.